Literature DB >> 10918437

Successful autologous bone marrow transplant without the use of blood product support.

K K Ballen1, P A Ford, H Waitkus, R V Emmons, W Levy, P Doyle, F M Stewart, P J Quesenberry, P S Becker.   

Abstract

We describe a successful autologous bone marrow transplant without the use of any blood products. The patient had relapsed large cell lymphoma. He was a Jehovah's Witness and would not accept transfusions of red blood cells or platelets. He enrolled in our Bloodless Medicine and Surgery Program and was maintained on a regimen of erythropoietin, iron, Amicar, and G-CSF throughout the transplant. He tolerated the transplant well and is alive with no evidence of disease 10 months after autografting.

Entities:  

Mesh:

Year:  2000        PMID: 10918437     DOI: 10.1038/sj.bmt.1702483

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  3 in total

1.  Bloodless cancer treatment results of patients who do not want blood transfusion: single center experience of 77 cases.

Authors:  Sung Yong Oh; Sung-Hyun Kim; Hyuk-Chan Kwon; Suee Lee; Kyeong Hee Kim; Kyung A Kwon; Jong-Hwan Lee; Kyu-Yeol Lee; Hyo-Jin Kim
Journal:  Support Care Cancer       Date:  2009-10-20       Impact factor: 3.603

2.  Autologous and allogeneic stem cell transplant in Jehovah's Witnesses: a single-center experience on 22 patients.

Authors:  P Mazza; G Palazzo; C Minoia; B Amurri; G Pisapia
Journal:  Bone Marrow Transplant       Date:  2016-03-07       Impact factor: 5.483

Review 3.  Successful autologous peripheral blood stem cell transplantation in a Jehovah's Witness with multiple myeloma: review of literature and recommendations for high-dose chemotherapy without support of allogeneic blood products.

Authors:  S Schmitt; V Mailaender; G Egerer; A Leo; S Becker; P Reinhardt; M Wiesneth; H Schrezenmeier; A D Ho; H Goldschmidt; T M Moehler
Journal:  Int J Hematol       Date:  2008-03-04       Impact factor: 2.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.